241 related articles for article (PubMed ID: 10178497)
1. A cost-effectiveness clinical decision analysis model for schizophrenia.
Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
[TBL] [Abstract][Full Text] [Related]
2. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.
Palmer CS; Brunner E; Ruíz-Flores LG; Paez-Agraz F; Revicki DA
Arch Med Res; 2002; 33(6):572-80. PubMed ID: 12505105
[TBL] [Abstract][Full Text] [Related]
3. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
Almond S; O'Donnell O
Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
6. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
Bounthavong M; Okamoto MP
J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
Foster RH; Goa KL
Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
[TBL] [Abstract][Full Text] [Related]
8. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
Laux G; Heeg B; van Hout BA; Mehnert A
Pharmacoeconomics; 2005; 23 Suppl 1():49-61. PubMed ID: 16416761
[TBL] [Abstract][Full Text] [Related]
9. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
[TBL] [Abstract][Full Text] [Related]
10. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
Taylor DM; Wright T; Libretto SE;
J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
[TBL] [Abstract][Full Text] [Related]
11. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
Lubinga SJ; Mutamba BB; Nganizi A; Babigumira JB
Appl Health Econ Health Policy; 2015 Oct; 13(5):493-506. PubMed ID: 25958192
[TBL] [Abstract][Full Text] [Related]
12. [Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain].
Sacristán JA; Gómez JC; Salvador-Carulla L
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(4):225-34. PubMed ID: 9412161
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
[TBL] [Abstract][Full Text] [Related]
15. [Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France].
Le Pen C; Lilliu H; Allicar MP; Olivier V; Gregor KJ
Encephale; 1999; 25(4):281-6. PubMed ID: 10546082
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.
Revicki DA
Schizophr Res; 1999 Mar; 35 Suppl():S101-9. PubMed ID: 10190231
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
Hamilton SH; Revicki DA; Edgell ET; Genduso LA; Tollefson G
Pharmacoeconomics; 1999 May; 15(5):469-80. PubMed ID: 10537964
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
[TBL] [Abstract][Full Text] [Related]
19. Cost evaluation of risperidone compared with olanzapine.
Byerly MJ; Weber M; Brooks D; Casey SB; Elliot S; Hawkins J
Psychiatr Serv; 2003 May; 54(5):742-4. PubMed ID: 12719509
[TBL] [Abstract][Full Text] [Related]
20. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
